| HOME >> BIOLOGY >> TECHNOLOGY |
5. Development code RTU-1096 (dermatological and neurological diseases)
This compound newly developed by R-Tech Ueno demonstrates an unconventional action, VAP-1* inhibition. We intend to develop this compound as a drug indicated for atopic dermatitis, contact dermatitis and psoriasis vulgaris in the dermatological field, and diabetic neuropathy in the neurological field.
We plan to report on the development status of each item on the home page of R-Tech Ueno.
*VAP-1 inhibitor
Vascular adhesion protein-1 (VAP-1) is also called semicarbazide-sensitive amine oxidase (SSAO). There are two types of VAP-1/SSAO, that is, the membrane-binding type present in the vascular endothelium and the free type present in the serum. The former serves as a molecule adherent to white blood cells and lymphocytes and is involved in inflammation while the latter detoxifies amine in the living body by its amine oxidase activity. In other words, VAP-1 is a protein that demonstrates two different functions. The increase in VAP-1/SSAO activity is observed in the serum and various tissues of patients with diabetes mellitus, atopic dermatitis, obesity, arteriosclerosis, heart disease, etc. In this regard, VAP-1 inhibitor inhibits the excessive function of VAP-1/SSAO.
About R-Tech Ueno, Ltd.
Representative Director & President: Yukihiko Mashima
Head Office: 1-1-7 Uchisaiwai-cho, Chiyoda-ku, Tokyo
Code No.4573, Osaka Securities Exchange; Hercules
CONTACT: Koji Nakamura
Business Management Department
R-Tech Ueno, Ltd.
Tel: +81-3-3596-8011
e-mail: koji.na
'/>"/>
| SOURCE R-Tech Ueno, Ltd. Copyright©2009 PR Newswire. All rights reserved |